Business Context and Reporting Period
Company: Omeros Corporation (OMER)
Filing Type: Form 8-K (Current Report)
Report Date: May 13, 2026
Reporting Period: Three months ended March 31, 2026
Item Reported: Item 2.02 Results of Operations and Financial Condition
This filing serves as a notification that Omeros Corporation issued a press release on May 13, 2026, announcing its financial results for the first quarter of 2026. The press release is included as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover sheet for the Form 8-K and does not contain specific financial data points. The actual figures for revenue, profit, cash flow, margins, debt, and liquidity are contained within the referenced press release (Exhibit 99.1), which is not included in the input text.
- Revenue: Not provided in filing text.
- Net Income/Loss: Not provided in filing text.
- Cash Flow: Not provided in filing text.
- Debt and Liquidity: Not provided in filing text.
Material Changes
The filing text does not provide specific comparative data or details regarding material changes versus the prior comparable period. Investors must refer to the attached press release (Exhibit 99.1) for year-over-year or quarter-over-quarter analysis.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the issuance of a press release by the company but does not include the text of the commentary, guidance, or outlook within this document.
Risks and Contingencies: No specific risks or contingencies are detailed in the cover sheet. The filing includes a standard disclaimer stating that the information in the 8-K and its exhibits shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into other SEC filings.
Investor Verification Checklist
- Verify the specific financial results (revenue, net loss, cash position) by reviewing the full text of the press release dated May 13, 2026 (Exhibit 99.1).
- Confirm whether the company provided updated financial guidance or clinical trial milestones in the referenced press release.
- Check the Nasdaq Stock Market listing status for OMER to ensure continued compliance with listing standards based on the reported financial condition.
- Review the full 10-Q filing (when available) for the three months ended March 31, 2026, for audited or reviewed financial statements.